elacestrant sold brand name orserdu anticancer medication used treatment breast taken elacestrant antiestrogen antagonist estrogen receptors biological targets endogenous estrogens common side effects elacestrant include musculoskeletal pain nausea increased cholesterol elevated liver enzymes increased triglycerides fatigue decreased hemoglobin vomiting increased alt increased ast decreased sodium increased creatinine decreased appetite diarrhea headache constipation abdominal pain hot flashes upset elacestrant approved medical use united states january european union september elacestrant indicated treatment postmenopausal women adult men estrogen receptor erpositive human epidermal growth factor receptor advanced metastatic breast cancer disease progression following least one line endocrine elacestrant antiestrogen antagonist estrogen receptors biological targets endogenous estrogens like specifically antagonist estrogen receptor alpha elacestrant also selective estrogen receptor degrader serd induces degradation oral bioavailability elacestrant approximately plasma protein binding greater independent elacestrant metabolized liver primarily cytochrome enzyme lesser extent elimination halflife elacestrant excreted feces efficacy evaluated emerald randomized openlabel activecontrolled multicenter trial enrolled postmenopausal women men erpositive advanced metastatic breast cancer participants participants required disease progression one two prior lines endocrine therapy including one line containing eligible participants could received one prior line chemotherapy advanced metastatic participants randomized receive elacestrant mg orally daily investigator choice endocrine therapy included fulvestrant aromatase inhibitor randomization stratified mutation status detected vs detected prior treatment fulvestrant yes vs visceral metastasis yes vs mutational status determined blood circulating tumor deoxyribonucleic acid ctdna using cdx assay limited missense mutations ligand binding fda granted application elacestrant priority review fast track nonsteroidal combined selective estrogen receptor modulator serm selective estrogen receptor degrader serd described sermserd hybrid ssh discovered eisai development radius health takeda treatment estrogen receptor erpositive advanced breast elacestrant dosedependent tissueselective estrogenic antiestrogenic activities biphasic weak partial agonist activity er low doses antagonist activity higher shows agonistic activity bone antagonistic activity breast uterine unlike serd fulvestrant elacestrant able readily cross bloodbrainbarrier central nervous system target breast cancer metastases orally bioavailable require intramuscular httpsenwikipediaorgwikielacestrant